ITeos Therapeutics Inc (NASDAQ: ITOS)’s stock price has increased by 0.63 compared to its previous closing price of 9.55. However, the company has seen a 5.95% increase in its stock price over the last five trading sessions. investors.com reported 2024-09-16 that Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
Is It Worth Investing in ITeos Therapeutics Inc (NASDAQ: ITOS) Right Now?
Additionally, the 36-month beta value for ITOS is 1.36. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ITOS is 28.08M and currently, short sellers hold a 17.15% ratio of that float. The average trading volume of ITOS on October 18, 2024 was 541.72K shares.
ITOS’s Market Performance
ITOS’s stock has seen a 5.95% increase for the week, with a -17.08% drop in the past month and a -38.91% fall in the past quarter. The volatility ratio for the week is 5.56%, and the volatility levels for the past 30 days are at 5.12% for ITeos Therapeutics Inc The simple moving average for the last 20 days is -3.03% for ITOS stock, with a simple moving average of -27.67% for the last 200 days.
Analysts’ Opinion of ITOS
Many brokerage firms have already submitted their reports for ITOS stocks, with Wells Fargo repeating the rating for ITOS by listing it as a “Overweight.” The predicted price for ITOS in the upcoming period, according to Wells Fargo is $31 based on the research report published on August 13, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ITOS reach a price target of $37. The rating they have provided for ITOS stocks is “Buy” according to the report published on May 05th, 2021.
Robert W. Baird gave a rating of “Outperform” to ITOS, setting the target price at $45 in the report published on October 08th of the previous year.
ITOS Trading at -27.92% from the 50-Day Moving Average
After a stumble in the market that brought ITOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.75% of loss for the given period.
Volatility was left at 5.12%, however, over the last 30 days, the volatility rate increased by 5.56%, as shares sank -14.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.86% lower at present.
During the last 5 trading sessions, ITOS rose by +5.95%, which changed the moving average for the period of 200-days by -17.08% in comparison to the 20-day moving average, which settled at $9.91. In addition, ITeos Therapeutics Inc saw -12.24% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ITOS
Current profitability levels for the company are sitting at:
- -6.11 for the present operating margin
- 0.95 for the gross margin
The net margin for ITeos Therapeutics Inc stands at -4.56. The total capital return value is set at -0.2. Equity return is now at value -16.80, with -14.86 for asset returns.
Based on ITeos Therapeutics Inc (ITOS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -20.66. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -17.7.
Currently, EBITDA for the company is -143.99 million with net debt to EBITDA at 1.76. When we switch over and look at the enterprise to sales, we see a ratio of 4.45. The receivables turnover for the company is 0.56for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.08.
Conclusion
In conclusion, ITeos Therapeutics Inc (ITOS) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
